SUMMARY
Negative alterations of mitochondria are known to occur in heart failure (HF). This study investigated the novel mitochondrial-targeted therapeutic agent elamipretide on mitochondrial and supercomplex function in failing human hearts ex vivo. Freshly explanted failing and nonfailing ventricular tissue from children and adults was treated with elamipretide. Mitochondrial oxygen flux, complex (C) I and CIV activities, and in-gel activity of supercomplex assembly were measured. Mitochondrial function was impaired in the failing human heart, and mitochondrial oxygen flux, CI and CIV activities, and supercomplex-associated CIV activity significantly 
MITOCHONDRIAL DYSFUNCTION AND CARDIOLIPIN IN HEART FAILURE
A substantial body of work has implicated abnormal mitochondrial function and consequent impaired energy production via oxidative phosphorylation as a factor in the development of heart failure (HF), leading to heightened interest in mitochondrial function as a therapeutic target (1) (2) (3) . Efficient mitochondrial function is considered especially essential in the heart due to the sustained energy requirements of the myocardium. Cardiolipin, a unique phospholipid with 4 fatty acid side chains, is critical for maintaining normal adenosine triphosphate generation by anchoring the proteins of the electron transport chain onto the inner mitochondrial membrane architecture (4) . In the heart, a mitochondrial inner membrane enriched with tetralinoleoyl cardiolipin (containing 4 linoleic acid side chains) facilitates the stability of the physical interaction between oxidative phosphorylation complex protein multimers in what has been termed the mitochondrial supercomplex, composed of complex (C) I, CIII, and CIV (5, 6) . Abnormalities in cardiolipin composition lead to mitochondrial dysfunction in the failing heart through disruption of the supercomplex and can be improved with dietary interventions in rodent models (7) (8) (9) . These abnormalities in mitochondrial function have led to heightened interest in mitochondria as a therapeutic target in HF (3) .
ELAMIPRETIDE, A MITOCHONDRIAL-TARGETED PEPTIDE
Elamipretide (formerly referred to as Bendavia, MTP-131, and SS-31) is an aromatic-cationic, cell-permeable tetrapeptide in a new class of mitochondrial-targeted drugs and is the first in its class to enter clinical trials in patients with HF (10) (11) (12) . The peptide is targeted to mitochondria via cardiolipin where it has been shown in animal models to improve energetics and decrease reactive oxygen species, possibly by stabilizing the mitochondrial membrane and cytochrome c (13, 14) .
Elamipretide rapidly enters tissue (within minutes of treatment) and has cardioprotective effects in ischemia/reperfusion injury in animal models (15) (16) (17) (18) .
To date, there are no data on the direct effects of elamipretide, or other members of this novel class, on mitochondrial function in the human heart.
ELAMIPRETIDE IN HUMAN HF
The purpose of the present study was to investigate the effects of elamipretide on human cardiac mitochondrial function. Because this study was ex vivo and performed over the course of a few hours (too rapid to induce cardiolipin remodeling), any effects of the drug would likely be independent of cardiolipin molecular species alterations. Using freshly explanted human hearts, the current study found that: 1) elamipretide improves impaired mitochondrial function in HF, with no effect on normal mitochondrial function in nonfailing hearts; 2) elamipretide improves mitochondrial supercomplex function (CI, CIII, and CIV) but does not alter CII or CV activity; and 3) the short-term action of elamipretide is independent of any changes in cardiolipin side chain composition. Chatfield et al.
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concentration was determined by the plateau of a doseresponse curve in a subset of samples (data not shown).
Unless otherwise noted, all other chemicals were from MilliporeSigma (Burlington, Massachusetts).
PATIENT SAMPLES. Explanted cardiac ventricular tissue from children and adults of all races, sexes, and ethnic backgrounds with informed consent obtained from the subjects or their guardians were available for this study through the institutional review board- After incubation, tissue was cut into approximately 2-mg pieces and teased using forceps to separate fibers.
The tissue was then placed in a solution of BIOPS containing 30 mg/ml saponin for 30 min to permeabilize the plasma membrane and to allow substrate delivery to the mitochondria. Fibers were washed for 10 min at 4 C in ice-cold mitochondrial respiration medium containing 25 mM blebbistatin AE 100 mM elamipretide (26) . Samples were blotted on filter paper, weighed, and placed in the chambers of the Oroboros O2K apparatus at 37 C containing respiration medium and 25 mM blebbistatin AE 100 mM elamipretide. Standard protocols were followed for calibration of the chambers and followed by stepwise addition of 5 mM pyruvate, 1 mM malate, 4 mM adenosine diphosphate (ADP), 10 mM glutamate, 10 mM succinate, 10 mM cytochrome c, and either 2 mg/ml oligomycin or 0.5 mM steps of carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (until the maximum rate was reached) followed by 2 mM rotenone. Oxygen flux rates were normalized per milligram of tissue wet weight. Lipids, Alabaster, Alabama) (20, 27) . Cardiolipin species were quantified per milligram of protein.
STATISTICAL ANALYSIS. Statistical analyses were performed by using Prism software version 6.0 Chatfield et al.
(GraphPad Software, La Jolla, California). Treatment effects were analyzed by using a ratio-paired Student's t-test, with p < 0.05 being significant and p < 0.1 reported as trending toward significance (28) . HF or time-based effects were analyzed by using an un- Figure 1 . indicates a trend toward decreasing in HF ( Figure 2D ).
Abbreviations as in
There was no change in RCR with elamipretide treatment in nonfailing hearts ( Figure 2E) , whereas in HF, RCR was significantly increased with elamipretide treatment ( Figure 2F ).
ACTIVITIES OF MITOCHONDRIAL CI AND CIV IN SUBSARCOLEMMAL MITOCHONDRIA ARE INCREASED
WITH ELAMIPRETIDE. Freshly isolated subsarcolemmal and interfibrillar mitochondria treated with elamipretide were used to measure total activity of CI and CIV as well as citrate synthase, a soluble enzyme in the mitochondrial matrix (29) . Total CI activity was significantly lower in HF compared with nonfailing samples ( Figure 3A) , whereas CIV activity in subsarcolemmal mitochondria showed a trend toward a decrease in HF ( Figure 3B) . No difference in citrate synthase activity was observed between HF and the nonfailing group ( Figure 3C ). In nonfailing subsarcolemmal mitochondria, activities of these 3 enzyme complexes were unaffected by elamipretide treatment ( Figures 3D to 3F ). However, in failing subsarcolemmal mitochondria, both CI and CIV activities exhibited a trend for increase by elamipretide treatment ( Figures 3G and 3H ), while citrate synthase activity was unchanged ( Figure 3I) . None of the enzyme activities was altered in the elamipretidetreated interfibrillar mitochondria (data not shown). Abbreviations as in Figure 1 .
SUPERCOMPLEX-ASSOCIATED CIV ACTIVITY IS ALTERED WITH ELAMIPRETIDE. BN PAGE in-gel
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A P R I L 2 0 1 9 : 1 4 7 -5 7 activity was used to separate supercomplex from free CIV. Figure 4A shows representative gels for CI, CII, CIV, and CV activities. CIV activity is present in a free state, within the supercomplex, and in intermediate molecular weight forms not analyzed in this study. CI is only present in its supercomplex form. When these bands were quantified, the quantity of CIV in the supercomplex was not altered in HF ( Figure 4B ), whereas the free CIV activity was significantly lower ( Figure 4C) . In nonfailing samples, elamipretide treatment had no effect on CIV regardless of whether it is bound or free ( Figures 4D and 4E ). By contrast, in HF, the activity of CIV in the supercomplex was significantly higher after elamipretide treatment, whereas activity of free CIV was unchanged ( Figures 4F and 4G ). There were no significant changes detected in the activities of CI, CII, or CV in HF or with elamipretide treatment according to this assay (data not shown).
CARDIOLIPIN COMPOSITION IS NOT ALTERED WITH ELAMIPRETIDE
TREATMENT. Tetralinoleoyl cardiolipin, the predominant cardiac cardiolipin species, with 4 linoleic acids and a mass-to-charge ratio of 1448, is shown as a percentage of the total (11 major species were used for total) cardiolipin content. The percentage of tetralinoleoyl cardiolipin was significantly lower in HF, consistent with our previously reported findings ( Figure 5A ), but elamipretide treatment had no effect on tetralinoleoyl cardiolipin in nonfailing or HF samples ( Figures 5B and 5C ) (7, 30) .
Cardiolipin absolute amounts, percent totals of 8 major cardiolipin species, monolysocardiolipin, or the sum of all cardiolipin species were unaltered after elamipretide treatment (data not shown). Untr ¼ untreated; other abbreviations as in Figure 1 .
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Chatfield et al. was that the biopsy specimens were pretreated with the compound during the ischemic stress followed by a demonstration of attenuation of mitochondrial dysfunction in the ex vivo study. Similar to our findings in the heart, there was no effect of elamipretide on mitochondrial function in the control renal biopsy specimen. Importantly, our study is the first to report the ability to improve mitochondrial dysfunction in human disease with acute treatment with elamipretide. Chatfield et al.
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